MicroRNA-9 和microRNA-210 检测联合 彩色多普勒超声诊断乳腺癌的价值

Value of miRNA-9 and miRNA-210 combined with color Doppler ultrasonography in diagnosis of breast cancer

摘要:

目的 探讨microRNA-9（miR-9）和microRNA-210（miR-210）检测联合彩色多普勒超声诊 断乳腺癌的价值。方法 选取2015 年3 月至2018 年3 月四川省人民医院东院乳腺外科收治的乳腺癌患者175 例（乳腺癌组）和乳腺良性病变患者162 例（良性病变组）。以是否患有乳腺癌为因变量，采用Logistic 回归 分析影响宫颈癌患病的影响因素；以术后病理检查结果作为金标准比较彩色多普勒超声，miR-9、miR-210 检测及联合诊断乳腺癌的准确性。结果 乳腺癌发病的危险因素包括乳腺癌家族史、月经规律与否、人表皮生长 因子受体2（HER2）表达、miR-9 表达和miR-210 表达（P <0.05）；彩色多普勒超声诊断乳腺癌的敏感性为 83.43%，特异性为69.14%。miR-9 检测诊断乳腺癌的曲线下面积（AUC）为0.753，miR-210 的AUC 为0.747。 彩色多普勒超声联合miR-9、miR-210 检测诊断为乳腺癌AUC 为0.934，敏感性为89.78%，特异性为85.12%。 结论 彩色多普勒超声联合血清miR-9、miR-210 检测可以较好地诊断乳腺癌，为临床早期诊断、筛查乳腺癌 提供参考。

Abstract:

Objective To explore the value of miRNA-9 and miRNA-210 combined with Doppler ultrasonography in the diagnosis of breast cancer. Methods A total of 175 patients with breast cancer (breast cancer group) and 162 patients with benign breast diseases (benign disease group) were enrolled in Eastern Hospital of Sichuan Provincial People's Hospital from March 2015 to March 2018. Using breast cancer as the dependent variable, logistic regression analysis was used to analyze the influencing factors of breast cancer prevalence. Postoperative pathological examination was used as the gold standard to explore the value of color Doppler ultrasonography, miRNA-9 and miRNA-210 in the diagnosis of breast cancer. Results The risk factors of breast cancer included family history of breast cancer, regular menstruation, and the expression levels of human epidermal growth factor receptor 2, miRNA-9 and miRNA-210 (P < 0.05). Color Doppler ultrasonographic diagnosis had a sensitivity of 83.43% and a specificity of 69.14% in the diagnosis of breast cancer. The AUC of miRNA-9 in the diagnosis of breast cancer was 0.753, and the AUC of miRNA-210 was 0.747. The AUC of color Doppler ultrasonogram combined with miRNA-9 and miRNA-210 in the diagnosis of breast cancer was 0.934, the sensitivity was 89.78%, and the specificity was 85.12%. Conclusions Color Doppler ultrasonography combined with serum miRNA-9 and miRNA-210 can be used to diagnose breast cancer and provide a new direction for early non-invasive diagnosis of breast cancer.